Clinical Outcomes Study Using a New Implantable Neurostimulation System for Chronic Intractable Pain
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01665040 |
Recruitment Status :
Completed
First Posted : August 15, 2012
Results First Posted : January 3, 2019
Last Update Posted : January 3, 2019
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Chronic Pain | Device: Neurostimulation device implantation | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 40 participants |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Precision Spectra™ Neurostimulator System for the Treatment of Chronic Intractable Pain of the Trunk and/or Limbs |
Actual Study Start Date : | August 2012 |
Actual Primary Completion Date : | May 2014 |
Actual Study Completion Date : | December 2014 |

Arm | Intervention/treatment |
---|---|
Experimental: Neurostimulation for chronic pain
Neurostimulation (spinal cord stimulation with or without peripheral nerve stimulation of the trunk) for chronic intractable pain of the trunk and/or limbs.
|
Device: Neurostimulation device implantation
Study subjects will undergo a screening-trial of neurostimulation using the Boston Scientific Corporation Precision Spectra neurostimulation system and may proceed to permanent implantation in the event of a successful screening trial. Treatment will include spinal cord stimulation and may also include peripheral nerve stimulation, based upon the physician's subject-specific treatment plan. |
- Proportion of Subjects Satisfied With Treatment at 90 Days Post-IPG Implantation [ Time Frame: 90-days post permanent implantation ]Proportion of subjects satisfied with treatment at 90 days post-IPG implantation, as measured by a 7-point Patient Satisfaction with Treatment (PSWT) questionnaire.
- Proportion of Subjects Satisfied With Treatment in a Sub-group Utilizing More Than 2 IPG Ports at 365 Days Post-IPG Implantation [ Time Frame: 365 days post permanent implantation ]Proportion of subjects in a sub-group utilizing more than 2 IPG ports at 365 Days post-IPG implantation satisfied with treatment, as measured by a 7-point Patient Satisfaction with Treatment (PSWT) questionnaire.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Chronic intractable pain of the trunk and/or limbs
- Documented history of trunk and/or limb pain of at least 180 days
- Overall pain intensity of at least 5 on a 0-10 numerical rating scale (OPI-NRS-11) over the past 180 days based on subject recall
- Pass study site's routine psychological/psychiatric evaluation within 180 days before signing the informed consent
- Subject is willing and able to comply with all protocol-required follow-up evaluations
- 18 years of age or older when written informed consent is obtained
- Subject signs informed consent
Exclusion Criteria:
- Unable to operate the Precision Spectra™ System either by self or with a caregiver
- Primary source of pain is cancer-related, pelvic, visceral, anginal or migraine
- Overall pain intensity of always 10 on a 0-10 numerical rating scale (OPI-NRS-11) over the past 180 days based on subject recall
- Is a high surgical risk
- Currently on any anticoagulant medications that cannot be discontinued during perioperative period
- Subject requires Magnetic Resonance Imaging (MRI) while implanted with lead(s) and/or the Precision Spectra IPG
- Subject is participating (or intends to participate) in another investigational drug or device clinical trial that may influence the data that will be collected for this study
- Subjects already implanted with an active implantable device(s) to treat their pain (IPGs, implantable drug pumps, etc) or pacemaker or Implantable Cardiac Defibrillator
- Patient is a woman who is pregnant (a urine pregnancy test must be performed within 7 days prior to the stimulation trial procedure in women of child-bearing potential) or nursing or intends to become pregnant during the course of the trial.
- Failed to achieve satisfactory relief during the stimulation trial phase
Responsible Party: | Boston Scientific Corporation |
ClinicalTrials.gov Identifier: | NCT01665040 History of Changes |
Other Study ID Numbers: |
A5004 |
First Posted: | August 15, 2012 Key Record Dates |
Results First Posted: | January 3, 2019 |
Last Update Posted: | January 3, 2019 |
Last Verified: | December 2018 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Keywords provided by Boston Scientific Corporation:
neurostimulation spinal cord stimulation peripheral nerve stimulation |
Additional relevant MeSH terms:
Chronic Pain Pain, Intractable Pain |
Neurologic Manifestations Nervous System Diseases Signs and Symptoms |